GSK raised its full-year projection on Wednesday, driven by demand for its blockbuster Shingrix vaccination, days after spinning off its consumer health company.
GSK estimates 2022 sales to expand 6% to 8% and adjusted operating profit to rise 13% to 15%, excluding COVID-19 contributions.
The company had predicted full-year sales growth of 5% to 7% and operating profit growth of 12-14%.
GSK expects demand for its shingles vaccine to rise as healthcare systems recover from COVID-19 vaccination programmes.
Shingrix produced 731 million pounds, significantly over GSK’s 610 million-pound projection.
GSK achieved 6.9 billion pounds ($8.32 billion), including pandemic solutions sales from the previous quarter, exceeding projected revenues of 6.3 billion pounds, a company-compiled consensus indicated.
Pandemic solutions sales have dropped.
As COVID headwinds abate and the U.S. health regulator rescinds the emergency use authorization for GSK’s therapy, Xevudy, due to concerns about its benefit against Omicron offshoot variants, second-quarter Xevudy sales fell to 466 million pounds, after generating about 1.3 billion pounds in the first quarter.
$1 = 0.8297 lbs.